naion semaglutide news Once-weekly doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes | International Journal of Retina and Vitreous The use of semaglutide in

In 2023, more than a dozen peptides were placed in Category 2 effectively barred from compounding on the grounds of potential safety concerns

With so little direct research, clinical guidelines often lean on what we can reasonably assume from the medication design and its composition, like its size, how the body absorbs it, and how likely it is to pass into breast milk, instead of real-world studies in breastfeeding mothers and babies

Ozempic, the brand name for semaglutide, is a GLP-1 receptor agonist used to treat type 2 diabetes and, more recently, obesity

That's the only thing we have today that tells us anything about a person's immune system